Catalent bags a German stem cell developer to build its next-gen therapeutics wing
Another day, another acquisition for CDMO giant Catalent. The New Jersey firm has now bought out Germany’s RheinCell Therapeutics, a specialist in human induced pluripotent stem cells, to build out its next-gen therapies wing.
The German company is based in Langenfeld, outside of Düsseldorf, around 2.5 hours’ drive from Catalent’s campus for cell and gene therapy in Gosselies, Belgium, allowing for efficient transfer. After the deal closes, which is expected before the end of 2021, RheinCell’s employees will join Catalent’s cell and gene therapy operations. The acquisition helps Catalent build upon its current cell therapy development and manufacturing capabilities.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,500+ biopharma pros reading Endpoints daily — and it's free.